Comparative Pharmacology
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FESOTERODINE FUMARATE versus LUSEDRA.
FESOTERODINE FUMARATE vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with highest affinity for M3 receptors; reduces detrusor muscle contractions and bladder overactivity.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
4 mg orally once daily; may be increased to 8 mg once daily based on tolerability.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5–10 hours) for the active metabolite (5-hydroxymethyl tolterodine, 5-HMT). The parent drug fesoterodine has a very short half-life (<1 hour) and is rapidly hydrolyzed to 5-HMT. Clinical context: steady-state achieved within 2–4 days of b.i.d. dosing.
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Primary route is renal (70% of administered dose as metabolites, 7% as unchanged drug). Hepatic metabolism with biliary/fecal elimination accounts for ~23% (primarily via CYP2D6 and CYP3A4).<|im_end|>
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category A/B
Category C
Anticholinergic
Anticholinergic